Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 7,735 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $4.80, for a total transaction of $37,128.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Cerus Co. (NASDAQ CERS) traded up $0.07 during midday trading on Wednesday, reaching $5.20. 111,470 shares of the company traded hands, compared to its average volume of 1,557,582. Cerus Co. has a twelve month low of $1.93 and a twelve month high of $5.43. The company has a current ratio of 3.89, a quick ratio of 3.26 and a debt-to-equity ratio of 0.77. The firm has a market cap of $654.47, a P/E ratio of -9.23 and a beta of 2.16.
Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Cerus had a negative net margin of 139.06% and a negative return on equity of 154.46%. The business had revenue of $16.20 million during the quarter, compared to the consensus estimate of $17.53 million. During the same quarter last year, the firm posted ($0.13) EPS. Cerus’s revenue was up 60.4% compared to the same quarter last year. sell-side analysts anticipate that Cerus Co. will post -0.43 EPS for the current fiscal year.
Several analysts have recently commented on CERS shares. Robert W. Baird reaffirmed a “buy” rating and set a $5.00 price objective on shares of Cerus in a research report on Friday, December 1st. BTIG Research reaffirmed a “neutral” rating on shares of Cerus in a research report on Friday, December 8th. BidaskClub downgraded shares of Cerus from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Zacks Investment Research downgraded shares of Cerus from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, ValuEngine raised shares of Cerus from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $5.00.
ILLEGAL ACTIVITY NOTICE: “William Mariner Greenman Sells 7,735 Shares of Cerus Co. (CERS) Stock” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2018/03/14/william-mariner-greenman-sells-7735-shares-of-cerus-co-cers-stock.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.